Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.

This is a multicenter prospective single arm phase II study, and the purpose of this study is to evaluate the safety and efficacy of orelabrutinib combined with obinutuzumab and lenalidomide in untreated marginal zone lymphoma. The primary objective was the best complete response rate (CRR).

Trial Details

NCT ID
NCT06454968
Phase
PHASE2
Sponsor
Peking Union Medical College Hospital
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Orelabrutinib, obinutuzumab, lenalidomide
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • Age ≥ 18 years, either sex.
  • Histopathologically confirmed B-cell non-Hodgkin lymphoma MZL (splenic, nodal, or extra-nodal).
  • At least 1 measurable lesion
  • Eligible for treatment: meets the GELF criteria, or has clinical symptoms/organ dysfunction related to the disease

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →